Media Development for Mammalian Cell Culture - Increasing titer can have a significant impact on the cost of goods sold. Case studies show that a fourfold improvement in titer reduces that cost by

ADVERTISEMENT

Media Development for Mammalian Cell Culture
Increasing titer can have a significant impact on the cost of goods sold. Case studies show that a fourfold improvement in titer reduces that cost by one-half.


BioPharm International
Volume 18, Issue 5


Geoffrey Hodge
Cell culture productivity has increased dramatically over the last few decades. This productivity increase is due in large part to significant process development efforts in this area, efforts traditionally justified by the economic benefit of improving productivity. The economic pressure to increase productivity has been highlighted in recent years by the success of monoclonal antibodies, some of which have market requirements in the hundred-kilogram-per-year range. The demand for such large quantities of protein has, in turn, triggered concerns about a potential shortage of manufacturing capacity, intensifying the pressure to boost cell culture productivity.1




Development scientists have responded to this challenge admirably. Monoclonal antibody titers in cell culture have increased roughly tenfold, from a few hundred milligrams per liter a decade ago to grams per liter today, with reports of titers in excess of 5 grams per liter. If an industry-wide shortage of bioreactor capacity fails to materialize, this will be due not only to the recent burst in the construction of new manufacturing capacity, but also to the reduction of demand resulting from improvements in cell culture productivity.2


Evolution of Mammalian Cell Culture Media
In addition to the strategic advantage of reducing the requirement for bioreactor capacity, increasing titer can have a significant impact on the cost of goods sold (COGS). Case studies show that a fourfold improvement in titer can cut COGS by one-half.3 Cell culture development has been so successful that downstream processing is beginning to surface in discussions as the next bottleneck to be addressed. Although the gain in COGS from increasing cell culture productivity may diminish due to the increasing impact of downstream steps as titers continue to improve, optimizing bioreactor output is still a primary concern for most companies.

The steady increase in cell culture productivity is the result of intensive efforts to understand and optimize all aspects of the cell culture production process.Improvements have been made in molecular biology, cell line construction and selection, media and feed development, and bioreactor operating parameters. But arguably it is media and feed development, particularly feed development, that has been responsible for the largest share of this improvement.

MEDIA DEVELOPMENT CONSIDERATIONS While the strategic impact of decreasing capacity requirements and COGS makes boosting productivity a primary goal, it is but one of several important aspects to be considered when selecting or developing media. Others include safety (to assure patients are not adversely affected by therapeutics intended to improve quality of life), quality, robustness, economics, and operability.

Safety Safety and the related requirements of product quality and regulatory compliance are achieved mainly through control of raw materials for media. Introduction of contaminants via raw materials may be possible at any step in a biomanufacturing process, but cell culture media pose a higher risk because the cell culture processes provide an opportunity for co-cultivation of microbes and replication of adventitious agents that may infect cells. This concern, which has been a driving force in the trend toward eliminating serum from media, has been deepened by an increasing awareness of transmissible spongiform encephalopathies.

Through good processing, controls, and documentation, manufacturers of serum may reduce the risk of a transmissible pathogen reaching patients. The impossibility of reducing the risk to zero, along with the increasing regulatory burden of assuring safety, has led to a strong effort to eliminate serum from cell culture media. This same concern has expanded to other animal-derived raw materials, and thus, many media are now "animal-free."

Quality Comparability questions can arise from changing media in an established process. Changes in media may directly impact product characteristics such as glycosylation, or may alter cell culture conditions, subsequently impacting downstream steps. Introduction of new raw materials may also introduce new contaminants into the process stream. Even animal-free media may contain contaminants such as endotoxins, mycotoxins, or immunogenic compounds.4 Changes to media in an established process must be carefully assessed.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here